Patents Assigned to Genzyme Corporation
  • METHODS OF MEASURING CELL VIABILITY IN TISSUE ENGINEERED PRODUCTS
    Publication number: 20140273050
    Abstract: This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventor: Yongzhong Wang
  • AMINE FUNCTIONAL POLYAMIDES
    Publication number: 20140275469
    Abstract: Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Pradeep DHAL, Kanwen Yang, Robert J. Miller, S. Randall Holmes-Farley
  • THERMO-SENSITIVE BONE GROWTH COMPOSITIONS
    Publication number: 20140271471
    Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
  • Oligosaccharide-protein conjugates
    Patent number: 8835614
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: September 16, 2014
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances
    Publication number: 20140255994
    Abstract: Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 11, 2014
    Applicant: Genzyme Corporation
    Inventors: Konstantin Konstantinov, Rahul Godawat, Veena Warikoo, Sujit Jain
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20140255381
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: September 18, 2013
    Publication date: September 11, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Elyse BOURQUE, Cassandra CELATKA, Bradford HIRTH, Markus METZ, Zhong ZHAO, Renato SKLERJ, Yibin XIANG, Katherine JANCSICS, John MARSHALL, Seng CHENG, Ronald SCHEULE, Mario CABRERA-SALAZAR, Andrew GOOD
  • Beta-actin and RPS21 promoters and uses thereof
    Patent number: 8829176
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: September 9, 2014
    Assignee: Genzyme Corporation
    Inventors: Scott D. Estes, Weiqun Zhang
  • PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES
    Publication number: 20140249165
    Abstract: Provided herein are methods of treatment of a cystic disease by administering a compound of Formula I. In certain embodiments, the compound for use in the methods provided herein is roscovitine or an analog thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 4, 2014
    Applicant: Genzyme Corporation
    Inventors: Nikolay O. BUKANOV, Oxana BESKROVNAYA
  • Internal clamp for surgical procedures
    Patent number: 8821849
    Abstract: One aspect of the present invention relates to a method of occluding a vascular site in a mammal, comprising the step of introducing into the vasculature of a mammal at or proximal to a surgical site, a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding a vascular site of said mammal, wherein said temporarily occluded vasculature site is kept in a substantially cylindrical shape.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 2, 2014
    Assignee: Genzyme Corporation
    Inventor: Alexander Schwarz
  • AMIDE DENDRIMER COMPOSITIONS
    Publication number: 20140235724
    Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 21, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Pradeep K. DHAL, David J. HARRIS, Stephen Randall HOLMES-FARLEY, Chad C. HUVAL, Vitaly NIVOROZHKIN, Bruce SHUTTS
  • Aliphatic amine polymer salts for tableting
    Patent number: 8808738
    Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: August 19, 2014
    Assignee: Genzyme Corporation
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
  • AMIDO-AMINE DENDRIMER COMPOSITIONS
    Publication number: 20140219951
    Abstract: Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: GENZYME CORPORATION
    Inventors: PRADEEP DHAL, S. Randall Holmes-Farley, Chad Huval, Steven C. Polomoscanik
  • Gene therapy for lysosomal storage diseases
    Patent number: 8796236
    Abstract: This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. The transgene product may be any that is deficient in a lysosomal storage disease.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: August 5, 2014
    Assignee: Genzyme Corporation
    Inventors: James Dodge, Seng Cheng
  • Perfusive Organ Hemostasis
    Publication number: 20140205542
    Abstract: Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.
    Type: Application
    Filed: March 25, 2014
    Publication date: July 24, 2014
    Applicants: Lahey Clinic, Inc., Genzyme Corporation
    Inventors: Jean-Marie Vogel, James A. Wilkie, Peter N. Madras
  • USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
    Publication number: 20140199399
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 17, 2014
    Applicants: The General Hospital Corporation, Genzyme Corporation
    Inventors: James B. STREISAND, Jesse D. ROBERTS, JR.
  • Synthesis of UDP-Glucose: -acylsphingosine glucosyl transferase inhibitors
    Patent number: 8779163
    Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: July 15, 2014
    Assignee: Genzyme Corporation
    Inventors: Bradford H. Hirth, Craig Siegel
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 8778967
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: July 15, 2014
    Assignee: Genzyme Corporation
    Inventors: Gary Bridger, Renato T Skelj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R Wilson, Jason B Crawford, Ernest J McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria R Di Fluri
  • MULTIMERIC CONSTRUCTS
    Publication number: 20140193411
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Application
    Filed: January 31, 2014
    Publication date: July 10, 2014
    Applicant: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth
  • Chemically Modified Dendrimers
    Publication number: 20140186291
    Abstract: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 3, 2014
    Applicant: Genzyme Corporation
    Inventors: Luis Z. Avila, Robert J. Miller, Lauren Elizabeth Young, Rajesh Vasant Kamath
  • Combination therapies for treating type 1 diabetes
    Patent number: 8758761
    Abstract: In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: June 24, 2014
    Assignees: University of Florida Research Foundation, Inc., Genzyme Corporation
    Inventors: Mark A. Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria, Tracey Lodie